A High-Speed Non-Invasive Brain-Computer Interface Platform

To restore control where movement ends



INTELIMENSA

The Problem

Over 100 Million People Live With Stroke, Spinal Cord Injury, Cerebral Palsy or ALS

Who have no reliable way to communicate, or interact with the world.

93.8 million
Stroke survivors globally[4]

17 million
Living with cerebral palsy[3]

15+ million
Living with spinal cord injury[1]

11.9 million
New yearly stroke cases[4]

250k–500k
Sustain a spinal cord injury every year[2]

32,000+
Living with ALS in the EU and UK[5]

Most assistive technologies still rely on residual muscle, voice, or eye movement (joysticks, switches, eye-gaze, EMG) — inputs many patients cannot reliably use.

The Burden

The Cost of Doing Nothing

ALS

€80,000+ per patient / year
24/7 care, ventilation, hospitalisation

Spinal Cord Injury

€130,000+ per patient / year
up to €200K in severe tetraplegia

Severe Stroke

€30,000+ per patient / year
motor-deficit subset, excludes acute care

Severe Cerebral Palsy

€40,000+ per patient / year
lifetime cost exceeds €1M per patient

Intelimensa costs €12,000 once: less than two months of ALS care.[6]

The Solution

The Fastest Non-Invasive Brain-Computer Interface



Intent → Action

Translates neural signals into **real-time digital control**



Hands-Free Communication

Type, click, speak-through-text, and control apps



Works When Muscles Don’t

Reliable even as speech and motor function decline
and **uses residual muscle** when available



Low-Effort Daily Use

Designed for daily use with **minimal fatigue**

Outcome: Restore autonomy — communication, choice, and connection

Our Technology

A Validated Product

TRL 6-7

demonstrated with real end-users in their actual operational environment



~150 bits/min

High-bandwidth non-invasive BCI

Hardware & Firmware

Fully developed proprietary hardware & firmware

~6 to 15× Higher Bandwidth[7]

Compared to other non-invasive solutions

>98%

Accuracy

~10 ms

Latency



“This is the only BCI interface that worked.”

— ARSLA, France’s leading national association in the fight against ALS

Nicolas

ALS · Paris · February 2026

Watch the case study



“When the future comes home - for people who can no longer move, this is a real opportunity.”

Mathias Kruse

ALS · Leipzig · March 2026



“This is different from every other BCI I’ve tried.”

Leon Jokinen

Tetraplegia · Munich · July 2026
experienced in testing multiple BCIs



Erin Taylor

ALS · Los Angeles · October 2026

Our Achievements

10 Years of Development, Validated in Patients

€1,000,000+
Non-dilutive funding
EU & national programmes

4 Patients
at home in Paris, Leipzig,
Munich & Los Angeles
23+ sessions incl. 20+ volunteers

Patents
US[8] & EU[9] granted
BCI technology protected

Robot Oct 2026
navigated around a room
by thought alone

International Traction

Partnerships & collaborations with leading ALS & MND organisations

ARSLA
Vaincre
la maladie
de Charcot

France's leading
ALS association

ALS-mobil e.V.

National German
ALS association

MANCHESTER 1824
The University of Manchester

MND creativity
research programme

MND Association

UK's leading
MND charity

8.https://patents.google.com/patent/US11157082B2/en
9.https://patents.google.com/patent/EP3843625B1/en

Why Now

BCI Has Gone Mainstream. Surgery Is Still the Bottleneck.



Capital is pouring into BCI

Neuralink raised $650M and Synchron $200M in 2025. In 2026, investment is spreading to non-invasive and rehabilitation interfaces.[10]



The need is proven, and mostly unmet

Only about 2% of people who need a communication aid receive one today.[11]



Non-invasive finally performs

Intelimensa reaches ~150 bits/min with no surgery: 6 to 15× other non-invasive systems.[7]

The window is open for a high-performance BCI patients can use at home, with no operating room.

Our Impact (SDGs)

Every Device Gives Someone Their Voice Back



Good Health and Well-being

Communication and control with no surgery, for people living with ALS, spinal cord injury, stroke or cerebral palsy. Priced below today's eye-gaze systems.

Target 3.8: access to quality health care for all[16]



Reduced Inequalities

People with severe paralysis take part again in conversations, decisions, family life and even professional life.

Target 10.2: Inclusion of all, irrespective of disability[16]



Decent Work

Hands-free computer control opens study, creative work and remote jobs to people who cannot move.

Target 8.5: Decent work for persons with disabilities[16]

3

patient organisations co-designing and testing
ARSLA · ALS-mobil · MND Association

6,500

people equipped by 2033 (base case)[14]

3

outcomes tracked for every user
communication · caregiver hours · quality of life

Impact is our business model: every device sold is one more person who can communicate.

Use Cases

One Headset, Many Ways Back to Independence



Computer & Phone Control

Forms, admin & work tasks

Care & Safety

Nurse, caregiver call

Smart Home & Environment

Lights, temperature, security, entertainment

Mobility & Assistive Devices

Wheelchair control, bed positioning, robotic arm

Symptom Reporting

Medication prompts + confirmation

Clinical & Research

Track progression, remote check-ins

The Market

A Focused Beachhead in a Global Market

Stroke • Spinal Cord Injury • Cerebral Palsy • ALS



16.7M people
€200B at device price
4 target conditions, worldwide[12]

67,600 people
€0.8B at device price
ALS + tetraplegia in the EU, UK and US[13]

6,500 users by 2033
€78M at device price cumulative ‘29-’33
Base case of our revenue plan[14]

We start where the need is highest and reimbursement exists: ALS and high spinal cord injury.

Go-to-market: through patient associations in France, Germany and the UK, priced within existing eye-gaze reimbursement

The Revenue Model

Projected Revenue 2027–2033 (base case)

€12,000
One-time device cost. No licence fees.

up to €15,000
Incumbent eye-gaze system (Tobii Dynavox)

~71%
Gross margin per device



Base case, Intelimensa forecast model v1[15]

The Competition

Current Assistive Technologies Performance



The Potential

Healthcare is Our Entry Market



Aerospace

- Cognitive monitoring and hands-free system control
- High-performance environments and training optimisation
- In discussions with EU & US innovation programmes



Gaming & Entertainment

- Hands-free control and immersive interaction
- New input layer for AR/VR and next-gen interfaces
- Potential partnerships with gaming and tech platforms

Same hardware. Same technology. New frontiers.

The Team

Founded by Neuroscientists

Patented technology developed over 10+ years at the Transylvanian Institute of Neuroscience

Founders



Raul Cristian Mureșan, PhD
CEO & Co-founder
Former Max Planck Group Leader, Founder of TINS & TENSS, serial science entrepreneur



Danko Nikolić, PhD
CSO & Co-founder
Former Max Planck Group Leader



Vasile Vlad Moca, PhD
CTO & Co-founder
Former Max Planck researcher



Harald Bârzan, PhD
Tech Lead & Co-founder

Executive Team



Tudor Pasc
Business Development Lead



Sorana Ciura, PhD
Clinical Testing Lead



Veronica Tomescu
Software Development Lead



Irina Patrichi
Marketing Lead

Advisor



Randal Schulhauser
MedTech Advisor
~40 years at Medtronic, 50+ patents

Supported by a wider team across engineering, operations and clinical work

The Ask

€2.5M Seed Round

24-month runway to CE marking and launch

What This Round Achieves:

- EU MDR class IIa CE marking and ISO 13485 quality system
- Clinical evaluation with ALS and spinal cord injury users at 3 partner sites (France, Germany, UK)
- 60 pilot devices deployed with patient organisations
- Everyday-use software: communication, mobility, smart home
- Reimbursement dossiers in 2 launch markets
- Launch-ready for first medical-device sales in 2029



Capital Allocation

INTELIMENSA

Help us restore independence through real-time neural control

Raising €2.5M · 24 months to CE marking and launch

Raul Cristian Mureșan, PhD · CEO

raul.muresan@intelimensa.com

+40 745 038 694

Tudor Pasc · Business Development

tudor.pasc@intelimensa.com

+40 753 461 740

intelimensa.com

References

1. World Health Organization, Spinal cord injury fact sheet. https://www.who.int/news-room/fact-sheets/detail/spinal-cord-injury
2. World Health Organization, International perspectives on spinal cord injury.
https://www.who.int/publications/i/item/international-perspectives-on-spinal-cord-injury
3. Cerebral palsy review, 17 million people worldwide. https://pubmed.ncbi.nlm.nih.gov/27188686/
4. World Health Organization, Stroke fact sheet (2021 data). https://www.who.int/news-room/fact-sheets/detail/stroke
5. ALS: 6.22 per 100,000 people (pooled European prevalence, Neuroepidemiology 2021) × EU27 + UK population (Eurostat 2025, ONS 2024).
https://karger.com/ned/article/55/5/342/825223/Estimated-Prevalence-and-Incidence-of-Amyotrophic
6. Berry et al., ALS US Economic Burden (2023); Achtert & Kerkemeyer, European ALS Cost Review (2021); NSCISC Facts & Figures (US SCI); McDaid et al., UK SCI Lifetime Cost Modelling (2019); WHO Global Stroke Fact Sheet; CDC Cerebral Palsy Cost of Illness. Device-vs-care comparison: €12,000 one-time price vs €80,000+ per ALS patient per year.
7. https://doi.org/10.48550/arXiv.2308.13232
8. US patent US11157082B2. https://patents.google.com/patent/US11157082B2/en
9. European patent EP3843625B1. https://patents.google.com/patent/EP3843625B1/en
10. Neuralink $650M Series E: TechCrunch, 2 June 2025. https://techcrunch.com/2025/06/02/elon-musks-neuralink-closes-a-650m-series-e
Synchron $200M Series D: Medtech Insight (Citeline), November 2025.
2026 trends: New Market Pitch, Brain-Computer Interface Funding Trends (2026). https://newmarketpitch.com/blogs/news/brain-computer-interface-funding-trends
11. Tobii Dynavox, Q2 2025 results presentation, via Investing.com.
https://www.investing.com/news/company-news/tobii-dynavox-q2-2025-slides-revenue-surges-38-amid-strategic-acquisitions-93CH-4141205
12. TAM: 16.7M people = 10% of 93.8M living with stroke (WHO, 2021) + 20% of 17M with cerebral palsy + 50% of 7.3M with neck-level spinal cord injury (Global Burden of Disease 2021) + ~272,000 with ALS. Valued at the €12,000 device price.
13. SAM: 67,600 people with ALS or tetraplegia in the EU27, UK and US. ALS prevalence 6.22 per 100,000 in Europe and 5.5 per 100,000 in the US (CDC National ALS Registry), 50% eligible. Spinal cord injury prevalence 223–755 per million (Wyndaele, Spinal Cord 2006), one-third tetraplegic, 30% eligible. Populations: Eurostat 2025, ONS 2024, US Census Bureau 2025.
14. SOM: users equipped 2029–2033 in the base case. EU launch 2029 after CE marking, US launch 2031, adoption rising from 0.4% to 5% of the eligible population per year.
15. Revenue and gross margin: base case of the Intelimensa forecast model v1. €12,000 per device; research-device sales in 2027–2028.
16. United Nations, Sustainable Development Goals: targets 3.8, 10.2 and 8.5. https://sdgs.un.org/goals